Evaluating exosome multiomics and clinical outcomes in sudden cardiac death patients
Early Evaluation of Exosome Multiomics and Clinical Prognosis in Patients With Sudden Death
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · NCT06856993
This study looks at how certain tiny particles in the blood are connected to sudden cardiac death in patients who had symptoms before their heart stopped, to help improve future care and prevention.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (other) |
| Locations | 1 site (Nanjing, Jiangsu) |
| Trial ID | NCT06856993 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the relationship between exosome multiomics and clinical prognosis in patients who experience sudden cardiac death (SCD), particularly in the context of acute coronary syndrome (ACS). It focuses on patients who have shown clinical symptoms prior to their sudden death and aims to gather data on the prevalence and characteristics of SCD in this population. The study will utilize standardized medical care protocols for cardiac arrest and analyze the collected data to improve understanding of SCD and its correlation with ACS. The findings may help inform future guidelines for prevention and treatment of ACS-related sudden death.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who have experienced sudden death with prior clinical symptoms and meet specific ACS diagnostic criteria.
Not a fit: Patients who died from accidental causes, chronic diseases, or natural causes are unlikely to benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the understanding of sudden cardiac death and lead to improved prevention strategies for patients at risk.
How similar studies have performed: While there is limited research specifically on exosome multiomics in this context, studies on sudden cardiac death and acute coronary syndrome have shown promising results in understanding these conditions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * The death event happens suddenly. * Age ≥ 18 years * The patient had obvious clinical symptoms 24 hours before treatment * Life expectancy exceeds 3 days * Proxy of patients signs the informed consent form * Comply with ACS diagnostic indicators recommended by ACC / AHA guidelines in 2016 Exclusion Criteria: * Death caused by accident, such as trauma, poisoning, etc. * Death from accidental or intentional overdose * Death from asphyxia * Death is caused by chronic disease or terminal illness * The patient died naturally * Has participated in other clinical studies * Immediate family members give up continuing treatment
Where this trial is running
Nanjing, Jiangsu
- Nanjing Drum Tower Hospital — Nanjing, Jiangsu, China (RECRUITING)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Sudden Cardiac Death, Exosome Multiomics, Clinical Prognosis